MX2020001761A - Analogo de peptido de oxintomodulina acilado. - Google Patents
Analogo de peptido de oxintomodulina acilado.Info
- Publication number
- MX2020001761A MX2020001761A MX2020001761A MX2020001761A MX2020001761A MX 2020001761 A MX2020001761 A MX 2020001761A MX 2020001761 A MX2020001761 A MX 2020001761A MX 2020001761 A MX2020001761 A MX 2020001761A MX 2020001761 A MX2020001761 A MX 2020001761A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide analog
- obesity
- overweightness
- pharmaceutical composition
- oxyntomodulin peptide
- Prior art date
Links
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 3
- 235000020824 obesity Nutrition 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000321 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102400000319 Oxyntomodulin Human genes 0.000 abstract 1
- 101800001388 Oxyntomodulin Proteins 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona a un análogo de péptido novedoso de oxintomodulina acilado y una composición farmacéutica que comprende el mismo para prevenir y tratar obesidad o sobrepeso, o diabetes acompañada por obesidad y sobrepeso. Los péptidos son superiores a aquellos de oxintomodulina natural en agonismo doble en receptores GLP-1 y glucagón y vida media in vivo más larga. Una composición farmacéutica, que comprende los péptidos es efectiva en el tratamiento de enfermedades metabólicas tal como obesidad y diabetes mellitus.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170103798 | 2017-08-16 | ||
| PCT/KR2018/009425 WO2019035672A1 (ko) | 2017-08-16 | 2018-08-16 | 아실화 옥신토모듈린 펩타이드 유사체 |
| KR1020180095717A KR102230363B1 (ko) | 2017-08-16 | 2018-08-16 | 아실화 옥신토모듈린 펩타이드 유사체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001761A true MX2020001761A (es) | 2020-07-29 |
Family
ID=65562699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001761A MX2020001761A (es) | 2017-08-16 | 2018-08-16 | Analogo de peptido de oxintomodulina acilado. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11236142B2 (es) |
| EP (2) | EP4079757A1 (es) |
| JP (2) | JP7211659B2 (es) |
| KR (2) | KR102230363B1 (es) |
| CN (3) | CN116854804A (es) |
| AU (1) | AU2018318672B2 (es) |
| BR (1) | BR112020003319A2 (es) |
| CA (1) | CA3073011C (es) |
| HR (1) | HRP20240371T1 (es) |
| IL (1) | IL272606A (es) |
| MX (1) | MX2020001761A (es) |
| PH (1) | PH12020500338A1 (es) |
| PL (1) | PL3670529T3 (es) |
| RS (1) | RS65414B1 (es) |
| RU (1) | RU2752787C1 (es) |
| SA (1) | SA520411366B1 (es) |
| SG (1) | SG11202001283PA (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296960A (en) * | 2020-04-20 | 2022-12-01 | Hanmi Pharm Ind Co Ltd | A compound for the prevention or treatment of hyperlipidemia that includes a trigonal glucagon/glp-1/gip receptor agonist or its conjugate and a method for using it |
| KR102154959B1 (ko) * | 2020-04-29 | 2020-09-10 | 동아에스티 주식회사 | 지속형 glp-1 및 글루카곤 수용체 이중작용제 |
| CN115975057B (zh) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | 一种可妥度肽的固相合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389648B (zh) * | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| US8680049B2 (en) * | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| AU2008365556A1 (en) * | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| EP2370461B1 (en) * | 2008-12-15 | 2013-10-02 | Zealand Pharma A/S | Glucagon analogues |
| WO2010096052A1 (en) * | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| EA201291234A1 (ru) * | 2010-06-24 | 2013-07-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| PE20181268A1 (es) * | 2011-06-17 | 2018-08-03 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y el uso del mismo |
| MX2014007120A (es) * | 2011-12-23 | 2015-03-05 | Boehringer Ingelheim Int | Analogos de glucagon. |
| WO2013157002A1 (en) * | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| JP6290193B2 (ja) * | 2012-06-04 | 2018-03-07 | オプコ バイオロジクス リミテッド | ペグ化ｏｘｍ変異体 |
| KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014152460A2 (en) * | 2013-03-15 | 2014-09-25 | Indiana University Research And Technology Corporation | Prodrugs with prolonged action |
| US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| CN104926934B (zh) * | 2014-09-23 | 2016-11-09 | 蒋先兴 | 胃泌酸调节素类似物 |
| US10232020B2 (en) * | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| WO2016090628A1 (zh) * | 2014-12-12 | 2016-06-16 | 北京韩美药品有限公司 | 胃泌酸调节肽(oxm)类似物、其合成及应用 |
| EP3310376A4 (en) * | 2015-06-17 | 2019-01-23 | The California Institute for Biomedical Research | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF |
| WO2017160669A1 (en) * | 2016-03-18 | 2017-09-21 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
-
2018
- 2018-08-16 CN CN202310958807.5A patent/CN116854804A/zh active Pending
- 2018-08-16 KR KR1020180095717A patent/KR102230363B1/ko active IP Right Grant
- 2018-08-16 SG SG11202001283PA patent/SG11202001283PA/en unknown
- 2018-08-16 CN CN202410003809.3A patent/CN117603337A/zh active Pending
- 2018-08-16 BR BR112020003319-7A patent/BR112020003319A2/pt unknown
- 2018-08-16 JP JP2020508489A patent/JP7211659B2/ja active Active
- 2018-08-16 CN CN201880053473.4A patent/CN111094331B/zh active Active
- 2018-08-16 EP EP22170622.9A patent/EP4079757A1/en active Pending
- 2018-08-16 MX MX2020001761A patent/MX2020001761A/es unknown
- 2018-08-16 AU AU2018318672A patent/AU2018318672B2/en active Active
- 2018-08-16 PL PL18846196.6T patent/PL3670529T3/pl unknown
- 2018-08-16 RS RS20240329A patent/RS65414B1/sr unknown
- 2018-08-16 RU RU2020108518A patent/RU2752787C1/ru active
- 2018-08-16 HR HRP20240371TT patent/HRP20240371T1/hr unknown
- 2018-08-16 CA CA3073011A patent/CA3073011C/en active Active
- 2018-08-16 EP EP18846196.6A patent/EP3670529B1/en active Active
- 2018-08-16 US US16/638,970 patent/US11236142B2/en active Active
-
2020
- 2020-02-11 IL IL272606A patent/IL272606A/en unknown
- 2020-02-14 PH PH12020500338A patent/PH12020500338A1/en unknown
- 2020-02-16 SA SA520411366A patent/SA520411366B1/ar unknown
- 2020-03-31 KR KR1020200039264A patent/KR102230368B1/ko active IP Right Grant
-
2021
- 2021-08-24 US US17/410,697 patent/US11713344B2/en active Active
- 2021-10-27 JP JP2021175902A patent/JP7443315B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500338A1 (en) | Acylated oxyntomodulin peptide analog | |
| PH12016500675A1 (en) | Acylated glucagon analogues | |
| PH12020551742A1 (en) | Gip derivatives and uses thereof | |
| EA201291234A1 (ru) | Аналоги глюкагона | |
| PH12015500531A1 (en) | Glucagon analogues | |
| MX2016004907A (es) | Analogos del glucagon. | |
| UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
| PH12014501336A1 (en) | Glucagon analogues | |
| MX2017012864A (es) | Analogo acilado del glucagon. | |
| MY188182A (en) | Acylated glucagon analogues | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| EA201291233A1 (ru) | Аналоги глюкагона | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
| MX2021003830A (es) | Uso terapéutico del glucagón y combinación que incluye el mismo. | |
| MX2022012708A (es) | Agonista doble de receptor de glp-1 y glucagon de larga accion. | |
| NZ724595A (en) | Glucokinase activator compositions for the treatment of diabetes | |
| TN2011000667A1 (en) | Acylated glucagon analogues | |
| EA201400536A1 (ru) | Способы получения двойных солей лоркасерина (варианты), продукты способов, двойные соли, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способ лечения и/или профилактики нарушений, связанных с ожирением |